Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 690517 dose-ranging trial alone and with empagliflozin in chronic kidney disease
2021-001434-19Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vicadrostat and empagliflozin in chronic kidney disease (CKD) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from treatment period baseline in log transformed urine albumin creatinine ratio. Started Oct 2021; status: completed.
02
Drugs
vicadrostatempagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2021-001434-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001434-19.